
|Articles|November 1, 2003
New drug targets considered for erectile dysfunction
Author(s)Robert H. Carlson
Paris-Basic research in erectile dysfunction therapy is being hamperedby the attitude of some funding bodies that phosphodiesterase type-5 inhibitorsalone have solved all problems, according to a special committee convenedat the 2nd International Consultation on Erectile and Sexual Dysfunctionshere.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
Phase 1/2 trial launches of molecular glue degrader for ccRCC
5






